Optimizing post–chimeric antigen receptor (CAR) T cell monitoring: Evidence across lisocabtagene maraleucel (liso-cel) pivotal clinical trials and real-world experience.
M. Kamdar(University of Colorado Cancer Center), Matthew A. Lunning(University of Nebraska Medical Center), Alberto Vasconcelos(Bristol-Myers Squibb (Switzerland)), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), David Bernasconi(Bristol-Myers Squibb (United States)), Alessandro Crotta(European Organisation for Rare Diseases), Iris Isufi(Yale University), Matthew J. Frigault(Harvard University), Bradley D. Hunter(Intermountain Healthcare), David B. Miklos(Stanford University), Marcelo C. Pasquini(Cleveland Clinic), Eric Bleickardt(Unknown), Jennifer L. Crombie(Dana-Farber Cancer Institute), Nausheen Ahmed(Health Care Foundation of Greater Kansas City), Miguel-Angel Perales(Memorial Sloan Kettering Cancer Center), Debasmita Roy(Bristol-Myers Squibb (United States)), Jeremy S. Abramson(Massachusetts General Hospital), Mazyar Shadman(University of Washington), Abu‐Sayeef Mirza(University of South Florida)
Cited by 0
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|723
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560